Current Takeaway
Persistent viral reservoirs and the reactivation of latent pathogens represent a primary biological model for the development and maintenance of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID. In this model, initial infections—such as acute COVID-19 or infectious mononucleosis—disturb immune homeostasis, leading to the failure of T-cell surveillance and the subsequent reactivation of dormant herpesviruses (such as Epstein-Barr virus, HHV-6, and varicella-zoster virus), the expression of ancient human endogenous retroviruses (HERVs), or the long-term persistence of SARS-CoV-2 in deep tissues. These persistent pathogens and their proteins act as chronic antigens, driving persistent systemic inflammation, neuroinflammation, and metabolic exhaustion.
Recent research has mapped specific entry points and immune evasion strategies of these viruses, demonstrating that Epstein-Barr virus utilizes the host receptor R9AP for universal cell entry and that acute COVID-19 promotes EBV reactivation by inducing replicative senescence in CD8+ T cells. Furthermore, evidence supports the presence of “abortive lytic reactivation,” where dormant viruses produce inflammatory proteins like dUTPase to trigger immune responses without completing a full replication cycle. Computational and clinical studies have also validated molecular mimicry, showing that antibodies generated against viral proteins cross-react with vital human central nervous system and vascular proteins, potentially driving autoimmune pathology.
While these mechanistic and observational insights are biologically plausible, significant uncertainties remain. The exact tissue location, viability, and replication capacity of persistent SARS-CoV-2 reservoirs have not been definitively confirmed in large live cohorts. In addition, the correlation between viral protein antibodies (such as anti-dUTPase IgG) and symptom severity does not prove a causal relationship, and targeted therapies—such as anti-CD80 monoclonal antibodies or long-course antivirals—require validation in double-blind, placebo-controlled clinical trials to establish their safety and efficacy.
Why This Matters
Mapping viral persistence and reactivation provides a concrete, biologically measurable link between the acute infectious onset of ME/CFS and Long COVID and their chronic, multi-system symptoms. By shifting the focus from generalized systemic distress to specific viral antigens (such as herpesvirus dUTPase, HERV-K/W proteins, and SARS-CoV-2 spike proteins), research defines clear, drugable targets. Identifying these pathways explains why standard antiviral courses or single-virus assessments often fail to capture the disease process, since pathobiology may involve multi-viral cooperation, abortive replication cycles, or persistent low-level reservoirs in sanctuary tissues. These findings guide the development of next-generation therapeutic trials, including selective B-cell depletion, HERV-targeting monoclonal antibodies, and metabolic restoration protocols.
State of Evidence
- Established: Acute infections like Epstein-Barr virus (EBV) and SARS-CoV-2 can trigger chronic, post-infectious fatigue syndromes. Latent herpesviruses reside long-term in human tissues and can reactivate under conditions of immune stress or cellular exhaustion.
- Plausible but early: Epstein-Barr virus uses the membrane protein R9AP as a universal receptor to infect both B cells and epithelial cells. Acute COVID-19 induces senescent phenotypes in CD8+ T cells, impairing host control and facilitating EBV reactivation. Persistent viral activity in ME/CFS and Long COVID involves abortive lytic reactivation, where viruses express immunogenic proteins like dUTPase without completing full replication. Molecular mimicry between herpesvirus proteins (like EBNA1) and central nervous system proteins (like Synapsin 1) drives cross-reactive autoantibodies that correlate with fatigue and autonomic symptoms. Reactivation of human endogenous retroviruses (HERVs), particularly HERV-K and HERV-W, occurs in response to environmental triggers, producing persistent antigens that drive neuroinflammation.
- Not established: Clear causal proof that persistent SARS-CoV-2 reservoirs or herpesvirus reactivations are the sole or primary drivers of ME/CFS and Long COVID symptoms. Clinical efficacy of targeted therapeutic candidates—such as anti-CD80 antibodies, valganciclovir, temelimab, or GLP-1 receptor agonists—in treating post-viral fatigue.
- Key limitations: Most clinical cohort studies linking viral reactivation or HERV expression to symptoms are small, single-center, or restricted by gender, limiting their generalizability. Computational predictions of molecular mimicry require extensive validation in live biological systems. Identifying low-level tissue reservoirs remains technologically challenging, as blood-based assays may not reflect localized sanctuary sites in the gut, brain, or bone marrow.
Timeline
2025-02-10 - Position paper establishes clinical trial roadmap for persistent SARS-CoV-2 reservoirs
A consensus position paper by global infectious disease experts established a formal research roadmap and clinical trial guidelines for targeting persistent SARS-CoV-2 reservoirs in patients with Long COVID. The authors synthesized biological evidence demonstrating that viral persistence in deep tissues drives chronic immune activation and local tissue inflammation. They outlined requirements for drug delivery, participant selection, and reservoir biomarkers to guide upcoming trials evaluating antivirals and monoclonal antibodies. This shift in research focus prioritizes identifying and clearing viral sanctuary sites rather than managing symptoms alone. However, the roadmap does not provide clinical trial data demonstrating the safety or efficacy of these proposed therapies. It also emphasizes that non-invasive biomarkers for tracking tissue-level viral reservoirs remain a critical, unresolved diagnostic need.
Sources:
2025-06-18 - Universal host cell receptor R9AP identified for Epstein-Barr virus entry
A landmark study identified R9AP as the first universal host receptor facilitating Epstein-Barr virus (EBV) entry into both epithelial cells and B cells. Using in vitro gene knockouts and neutralizing antibodies, researchers proved that R9AP binds directly to the viral gH/gL complex to trigger membrane fusion. Pinpointing this common cellular entry point provides a concrete molecular target for developing broad-spectrum vaccines and neutralizing monoclonal antibodies. This offers a therapeutic pathway to prevent primary infection and block the cellular uptake that leads to chronic latent reservoirs. Nonetheless, the discovery does not demonstrate that targeting R9AP can clear already established latent EBV reservoirs in patients. The clinical efficacy and safety of R9AP-blocking agents also remain untested in human clinical trials.
Sources:
2025-09-19 - Clinical study demonstrates molecular mimicry between Epstein-Barr virus and human proteins
A clinical study in women with Post-COVID Syndrome and ME/CFS demonstrated molecular mimicry between Epstein-Barr virus (EBV) and human proteins. Researchers found elevated IgG autoantibodies targeting human peptides involved in neuronal, vascular, and autonomic function (such as SRRM3, SLC24A3, TSPYL2, and TSPYL5) that share sequence homology with EBV. Crucially, the levels of these cross-reactive antibodies directly correlated with patient-reported severity of fatigue, pain, cognitive dysfunction, and autonomic symptoms. This provides a clear autoimmune mechanism explaining how a host response to a common viral trigger can lead to chronic neurological and vascular symptoms. However, the study does not prove that these autoantibodies are the direct cause of the symptoms rather than a secondary biomarker of immune dysregulation. The findings are also limited by a relatively small, female-only cohort, requiring validation in larger, sex-stratified patient groups.
Sources:
2025-10 - Diagnostic blood markers differentiate post-COVID-19 condition from ME/CFS and fibromyalgia, highlighting HERV-W ENV subgroup activation
Giménez-Orenga et al. (published in Brain, Behavior, & Immunity - Health) analyzed HERV-W ENV antigenemia, cytokines, anti-SARS-CoV-2 serology, and red blood cell parameters in 193 post-pandemic females (including post-COVID-19 condition, ME/CFS, fibromyalgia, and controls). Pathogenic HERV-W ENV protein was detected in subsets of all patient groups, with the highest prevalence in post-COVID-19 condition (48.5%) compared to fibromyalgia (33.3%), co-diagnosis (30%), ME/CFS (25%), and controls (8.9%). Post-COVID-19 condition patients exhibited a distinct signature, including lower ferritin, higher mean corpuscular hemoglobin concentration (MCHC), and elevated anti-SARS-CoV-2 IgE/IgM. ROC analysis using these variables differentiated post-COVID-19 condition from other conditions. However, the cohort was exclusively female, which limits generalizability to male patients, and the small sample size of the ME/CFS-only group (n = 12) limits statistical power. Additionally, the cross-sectional design cannot establish a causal relationship between HERV-W ENV activation, hematological/cytokine changes, and clinical symptoms.
Sources:
2025-10-10 - Single-cell transcription map defines immunological requirements for lifelong EBV control
An immunological study mapped the cellular immune response required for lifelong Epstein-Barr virus (EBV) control at single-cell resolution. Using single-cell RNA sequencing, researchers discovered that a specific population of Vδ1 γδ T cells destroys EBV-infected B cells using natural killer cell receptors. This map provides a critical baseline for understanding why some individuals fail to suppress latent EBV, potentially leading to reactivation and chronic disease. It also identifies Vδ1 T-cells as a potential candidate for targeted allogeneic cell therapies. However, the study did not analyze ME/CFS cohorts directly to verify if a functional defect in this T-cell subset is present in patients. Additionally, the therapeutic utility of Vδ1 T-cell transfer remains preclinical and has not been tested in human trials.
Sources:
2025-12-10 - Long COVID immune cells show exaggerated interferon response to viral mimics
A laboratory study found that immune cells (PBMCs) from Long COVID patients exhibit an exaggerated type I interferon (IFN-I) response when exposed to synthetic viral mimics. This hyperreactive response, mediated through the cGAS and RIG-I pathways, correlated directly with the severity of patient fatigue. These findings support the hypothesis that chronic post-viral symptoms are maintained by “trained immunity,” where cells are epigenetically primed to overreact to viral signals. This establishes a biological rationale for evaluating interferon-blocking therapies to treat post-viral fatigue. However, the study does not identify the specific epigenetic modifications that maintain this trained immune state. It also does not demonstrate that inhibiting the IFN-I pathway is safe or clinically effective in resolving Long COVID symptoms.
Sources:
2025-12-16 - Pathological model attributes post-viral syndromes to herpesvirus abortive lytic replication
A molecular review proposed a pathological model attributing ME/CFS and Long COVID to the cooperative, abortive lytic reactivation of multiple herpesviruses. The authors presented evidence that dormant viruses like EBV and HHV-6 can enter a partially active state, producing toxic proteins such as dUTPase without completing full replication. These proteins act as chronic inflammatory triggers, explaining why patients experience severe immune activation even when traditional viral load tests are negative. This model suggests that therapeutic strategies should shift from standard replication-dependent antivirals to agents targeting specific viral proteins. However, as a literature review, the study does not provide new experimental data validating this mechanism in a clinical cohort. It also does not establish the exact combinations of herpesviruses required to drive this pathology in individual patients.
Sources:
2026-01-01 - Anti-dUTPase antibodies validated as herpesvirus reactivation hallmark in ME/CFS
A longitudinal clinical study validated the abortive herpesvirus model by demonstrating significantly elevated IgG antibodies against viral dUTPase proteins in ME/CFS. Analyzing 873 serum samples, researchers found that 72.5% of ME/CFS patients had antibodies against dUTPase from multiple viruses (EBV, HHV-6, and VZV), which correlated with fatigue severity. This provides a validated serum biomarker to help diagnose ME/CFS and stratify patients by symptom severity. It also supports the theory that persistent, low-level multi-viral protein expression is a key driver of the chronic illness. However, the correlation between antibody levels and fatigue does not prove a direct causal relationship. The study also does not demonstrate that reducing dUTPase antibody levels through immunotherapies leads to clinical improvement.
Sources:
2026-02-11 - Metabolic review links spike protein-induced mitochondrial damage to impaired energy pathways
A physiological review established a metabolic framework linking SARS-CoV-2 spike protein-induced mitochondrial damage to cellular energy failure in Long COVID. The authors synthesized evidence showing that spike protein exposure impairs fatty acid oxidation and shifts cells toward premature carbohydrate reliance. This metabolic shift leads to a severely decreased lactate threshold and “inverse fat adaptation,” which may drive post-exertional malaise. The review identifies metabolic interventions, such as ketogenic diets and strategies to increase carbon dioxide levels (the Bohr effect), as potential therapeutic options. However, these proposed metabolic axes are based on theoretical models and exercise analogies rather than direct clinical trials. The study does not prove that dietary or respiratory interventions can successfully restore mitochondrial function or resolve symptoms in patients.
Sources:
2026-04-20 - Impaired CD8 T-cell markers during acute COVID-19 associated with Epstein-Barr virus reactivation
A cohort study of hospitalized COVID-19 patients demonstrated that acute SARS-CoV-2 infection impairs CD8 T-cell surveillance, facilitating Epstein-Barr virus (EBV) reactivation. Researchers detected EBV reactivation in 70% of patients, which associated with a senescent CD8 T-cell phenotype characterized by reduced CD28 and CD11a expression. This provides a clear immunobiological mechanism explaining how acute COVID-19 acts as a trigger for herpesvirus reactivation, a major risk factor for developing Long COVID. It highlights the potential value of monitoring EBV status during acute viral infections to identify patients at risk for chronic complications. However, because the study focused on hospitalized patients during the first pandemic wave, the findings may not generalize to mild infections or newer variants. The study also does not follow patients long-term to prove that this acute reactivation directly leads to chronic fatigue syndrome.
Sources:
2026-04-27 - Orexin and GLP-1 dysregulation linked to neuroendocrine-metabolic fatigue pathways
A physiological review mapped the dysregulation of the neuropeptide Orexin and the metabolic hormone Glucagon-Like Peptide-1 (GLP-1) in post-viral syndromes. The authors proposed a model where viral-induced neuroinflammation impairs Orexin signaling, leading to sleep-wake disturbances, and depletes GLP-1, exacerbating metabolic failure. This model suggests that GLP-1 receptor agonists and orexin modulators could serve as targeted treatments for ME/CFS and Long COVID. It also highlights how sexual dimorphism in these pathways might explain the female-biased prevalence of post-viral illnesses. However, these hormone-neuropeptide cycles have not been systematically measured or validated in large patient cohorts. The study does not prove that administering metabolic modulators can successfully reverse post-viral neuroendocrine dysfunction.
Sources:
2026-05-12 - Environmental triggers linked to endogenous retrovirus (HERV) reactivation in ME/CFS
A comprehensive review mapped the reactivation of human endogenous retroviruses (HERVs) in the pathogenesis of ME/CFS. Evidence indicates that environmental triggers reactivate HERV subfamilies (particularly HERV-K and HERV-W), producing viral proteins that act as chronic antigens to drive neuroinflammation. The review highlighted studies showing elevated HERV-K protein in patient duodenal tissues and locus-specific profiling that reveals patient-specific “HERV fingerprints.” This supports the development of objective diagnostic assays and clinical trials using HERV-targeting monoclonal antibodies like temelimab. However, the analyzed studies are limited by small cohort sizes and heterogeneous diagnostic criteria. It also remains unproven whether reactivated HERVs are direct drivers of the pathology or secondary consequences of broader epigenetic dysregulation.
Sources:
2026-05-13 - Computational screen predicts sequence mimicry between neurotropic herpesviruses and brain proteins
A computational in silico study identified extensive molecular mimicry between neurotropic herpesvirus antigens and human central nervous system proteins. The analysis revealed 91 shared pentapeptides, showing that Synapsin 1 (SYN1) shares multiple immunogenic motifs with EBV and HHV-6 antigens, alongside myelin proteins like MBP, MAG, and MOG. This structural mapping provides a plausible biochemical pathway explaining how immune responses to viral reactivation can cross-react to attack brain and nerve tissues. It offers specific molecular targets to guide the development of diagnostic autoantibody tests and highly targeted neuro-immunotherapies. However, as a strictly computational analysis, the study does not validate this cross-reactivity in patient blood samples or live models. It does not prove that these predicted antibodies are actually present in patients or that they cause pathological damage in vivo.
Sources:
2026-05-26 - Anti-CD80 monoclonal antibodies selectively destroy EBV-infected B cells without complement activation
A translational study developed chimeric monoclonal antibodies targeting CD80 (B7-1) to selectively eliminate Epstein-Barr virus (EBV)-infected B cells. Researchers demonstrated that CD80 is highly expressed on EBV-positive B cells and that anti-CD80 antibodies trigger NK-cell-mediated destruction (ADCC) of these cells. Crucially, this approach completely avoids complement-dependent cytotoxicity (CDC) and preserves host T-cell antiviral surveillance, offering a safer alternative to broad B-cell depletion. This provides a highly targeted clinical direction to selectively clear latent EBV reservoirs and pathogenic B-cell subsets without causing broad immunosuppression. However, the efficacy and safety of these engineered anti-CD80 antibodies have only been demonstrated in vitro and in animal models. Clinical trials are required to prove that this therapy can safely clear EBV reservoirs and improve symptoms in patients with post-viral conditions.
Sources:
2026-06-28 - Review reframes ME/CFS as a post-infectious disorder of impaired adaptive capacity and state-dependent pathology
In a systems biology review published in the Journal of Translational Medicine, researchers Paul Watton and Bhupesh K. Prusty proposed a unified mechanistic model of ME/CFS and Long COVID. The paper shifts the focus from behavioral frameworks to post-infectious biology, reframing ME/CFS as a disorder of impaired adaptive capacity. Key aspects of the model include: (1) abortive lytic reactivation of herpesviruses (e.g., HHV-6, EBV) where viral proteins like dUTPase sustain chronic inflammatory signaling without active lytic replication; (2) directionally discordant fibronectin biology, driving thrombo-inflammatory feedback and platelet/mast cell activation; (3) IgG-mediated entry into endothelial cells inducing mitochondrial fragmentation; and (4) state-dependent endothelial and systemic pathology, showing that cellular dysfunction in ME/CFS is quiescent at rest but revealed under exertional or orthostatic stress. As a narrative review, it synthesizes existing literature and proposes a theoretical framework rather than presenting new primary patient data, and these suggested pathways require further validation in larger, sex-stratified patient cohorts.
Sources:
Open Questions
- What are the molecular mechanisms by which different variants of SARS-CoV-2 (or other viruses) trigger the reactivation of specific herpesviruses?
- To what extent do persistent low-level viral reservoirs in deep tissues (e.g., gut mucosal tissues) sustain systemic immune dysregulation compared to abortive replication of herpesviruses?
- Can therapeutic targeting of the universal EBV receptor R9AP clear established latent EBV infection, or is it limited to preventing new infections?
- What are the long-term clinical safety and efficacy profiles of anti-CD80 chimeric monoclonal antibodies when used to eliminate EBV-transformed B-cell pools in autoimmune/post-viral patient cohorts?